BusinessLatestStatnewsApr 2

Lilly's obesity pill enters oral GLP-1 market, Novo reacts

Lilly's new oral GLP-1 medication for obesity is now available, expanding treatment options. Novo Nordisk is responding to this new competitor in the weight management space.

Lilly Obesity Glp1 Markets

0 upvotes

Source and timing

StatnewspublisherUpdated Apr 2

Open original source

What happened

Lilly's new oral GLP-1 medication for obesity is now available, expanding treatment options.

Why it matters

Novo Nordisk is responding to this new competitor in the weight management space.

Lilly's obesity pill enters oral GLP-1 market, Novo reacts

More from this part of the feed

This update is standing on its own right now.